Table 1.
Total (N = 278) | Type D (N = 59) | Non-type D (N = 219) | RR or mean difference | (95 % CI) | P value | ||
---|---|---|---|---|---|---|---|
Gender | Male | 230 (83) | 51 (86) | 179 (82) | 1 | ||
Female | 48 (17) | 8 (14) | 40 (17) | 0.74 | (0.37; 1.50) | 0.396 | |
Age mean (SD) | 62.6 (10.6) | 60 (12.3) | 63 (10.5) | 2.99 | (−0.35; 6.33) | 0.079 | |
Indication | Primary | 196 (71) | 43 (73) | 153 (70) | 1 | ||
Secondary | 82 (30) | 16 (27) | 66 (30) | 0.90 | (0.57; 1.43) | 0.652 | |
Comorbidity | Diabetes | 54 (19) | 12 (20) | 42 (19) | 1.06 | (0.60; 1.88) | 0.841 |
COPD | 32 (12) | 7 (12) | 25 (11) | 1.04 | (0.47; 2.28) | 0.924 | |
CVA | 12 (4) | 1 (2) | 11 (5) | 0.34 | (0.04; 2.56) | 0.368 | |
TIA | 7 (3) | 2 (3) | 5 (2) | 1.48 | (0.43; 7.46) | 0.360 | |
Etiology | Ischemic | 170 (61) | 35 (60) | 135 (62) | 1 | ||
Non-ischemic | 79 (28) | 21 (36) | 58 (27) | 0.89 | (0.71; 1.12) | 0.292 | |
Other | 29 (10) | 3 (5) | 26 (12) | 0.53 | (0.41; 0.68) | <0.001 | |
Smoking | 58 (21) | 20 (34) | 38 (17) | 1.95 | (1.24; 3.09) | 0.005 | |
Alcohol (use ≥1 glass/week) | 175 (74) | 34 (68) | 141 (74) | 0.91 | (0.74; 1.12) | 0.319 | |
LVEF, mean (SD, N = 262) | 30 (15) | 26 (14) | 30 (15) | −4.80 | (−9.35; −0.24) | 0.039 | |
NYHA class | I | 36 (13) | 6 (10) | 30 (14) | 1 | ||
II | 165 (62) | 33 (56) | 135 (57) | 0.85 | (0.38; 1.89) | 0.680 | |
III | 68 (25) | 18 (31) | 50 (23) | 1.20 | (0.90; 1.60) | 0.259 | |
Medication | Beta-blocker | 229 (82) | 52 (88) | 177 (81) | 1.07 | (1.097; 1.22) | 0.211 |
Amiodarone | 27 (10) | 8 (14) | 19 (9) | 1.55 | (0.72; 3.38) | 0.266 | |
Diuretics | 184 (67) | 44 (75) | 140 (64) | 1.16 | (0.97; 1.39) | 0.135 | |
Aldosterone antagonist | 90 (33) | 28 (48) | 62 (28) | 1.67 | (1.18; 2.35) | 0.006 | |
ACE-I/AT-II antagonist | 216 (78) | 44 (75) | 172 (79) | 0.95 | (0.81; 1.12) | 0.516 | |
Depressive symptoms (cutoff ≥8) | 42 (16) | 22 (39) | 20 (10) | 4.02 | (2.36; 6.82) | <0.001 | |
Anxiety symptoms (cutoff ≥8) | 66 (24) | 27 (47) | 39 (19) | 2.53 | (1.70; 3.75) | <0.001 | |
History of depressive disorder | 53 (19) | 26(44) | 27 (12) | 3.57 | (2.27; 5.64) | <0.001 | |
History of anxiety disorder | 21 (8) | 10(17) | 11 (5) | 3.37 | (1.51; 7.56) | 0.002 | |
Health status, mean (SD) | Physical functioning | 60 (28) | 50 (28) | 62 (28) | −11.6 | (−19.85; −3.39) | 0.006 |
Social functioning | 71 (29) | 58 (30) | 75 (27) | −17.11 | (−25.32; −8.87) | <0.001 | |
Role limitations (physical) | 45 (45) | 33 (42) | 47 (45) | −14.22 | (−27.45; 0.99) | 0.030 | |
Role limitations (emotional) | 67 (41) | 48 (45) | 72 (39) | −24.18 | (−37.48; −10.88) | 0.001 | |
Mental health | 74 (19) | 59 (21) | 78 (17) | −18.58 | (−24.73; −12.44) | <0.001 | |
Vitality | 57 (23) | 43 (19) | 60 (22) | −16.87 | (−23.36; −10.38) | <0.001 | |
Bodily pain | 75 (27) | 61 (30) | 78 (26) | −17.60 | (−26.39; −8.81) | <0.001 | |
General health | 52 (20) | 39 (18) | 55 (20) | −15.31 | (−21.12; −9.50) | <0.001 |
Presented as n (%) unless otherwise indicated
RR relative risk, CI confidence interval, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, TIA transient ischemic attack, LVEF left ventricular ejection fraction, NYHA New York Heart Association functional class